Latest CXCR4 Stories
RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
Scientists at A*STAR’s Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.
New knowledge of drug mechanism paves road to new treatment approaches for patients suffering from frequent bacterial infectionsSingapore, Nov 14, 2013 - (ACN Newswire)
The findings will help to identify which patients benefit TGFb inhibitory therapy.
A group of scientists led by UT Southwestern Medical Center has reported the first successful blocking of tumor development in a genetic mouse model of an incurable human cancer.